Related Experiment Video
Updated: Jul 6, 2026
Heterotopic Renal Autotransplantation in a Porcine Model: A Step-by-Step Protocol
Published on: February 21, 2016
Hematologic Considerations in Kidney Transplantation: Core Curriculum 2025
Leigh-Anne Dale1, Jason A Freed2
1Division of Nephrology, Boston, Massachusetts; Beth Israel Deaconess Medical Center, and Harvard Medical School, Boston, Massachusetts.
Insights
Hematologic abnormalities are common after kidney transplants but often benign. This guide helps differentiate harmless findings from serious conditions, improving patient safety and graft survival.
Area of Science:
- Nephrology
- Hematology
- Transplantation Medicine
Background:
- Hematologic abnormalities, including cytopenias and cytoses, are frequent post-kidney transplant.
- Many abnormalities are benign, stemming from immunosuppression, infection prophylaxis, or chronic kidney disease.
Purpose of the Study:
- To provide a Core Curriculum on common hematologic disorders after kidney transplantation.
- To guide clinicians in differentiating benign findings from those requiring intervention.
Main Methods:
- Distillation of evidence on common cytopenias (neutropenia, lymphopenia, anemia, thrombocytopenia, thrombotic microangiopathy) and cytoses (eosinophilia, lymphocytosis, erythrocytosis, thrombocytosis).
- Framing disorders by timing, mechanisms, drugs/pathogens, and decision checkpoints.
- Illustrating differentiation with five real-world cases.
Main Results:
- Common post-transplant hematologic abnormalities include neutropenia, lymphopenia, anemia, thrombocytopenia, thrombotic microangiopathy, eosinophilia, lymphocytosis, erythrocytosis, and thrombocytosis.
- Key conditions requiring prompt action include drug-induced marrow suppression, cytomegalovirus reactivation, antibiotic-triggered eosinophilia, posttransplant erythrocytosis, and thrombotic microangiopathy.
Conclusions:
- A problem-oriented approach aids in managing post-transplant hematologic abnormalities.
- This strategy can reduce unnecessary drug interruptions, optimize hematology referrals, and enhance patient safety and allograft longevity.
Abstract:
Hematologic abnormalities including both cytopenias and cytoses are the rule rather than the exception in the first year after kidney transplantation, yet many are benign reflections of immunosuppression, infection prophylaxis, or residual chronic kidney disease. In this Core Curriculum, we distill the evidence on the disorders clinicians encounter most often, cytopenias including neutropenia, lymphopenia, anemia, thrombocytopenia, and thrombotic microangiopathy, as well as cytoses including eosinophilia, lymphocytosis, erythrocytosis, and thrombocytosis. Each is framed by typical timing, dominant mechanisms, key drugs or pathogens, and decision making checkpoints. Five real-world cases illustrate how to differentiate harmless findings from conditions that mandate prompt action, such as drug-induced marrow suppression, cytomegalovirus reactivation, antibiotic-triggered eosinophilia, posttransplant erythrocytosis, and thrombotic microangiopathy. Adopting this problem-oriented approach can reduce unnecessary drug interruptions, target hematology referrals, and preserve both patient safety and allograft longevity.
Related Concept Videos
01:22Bone Marrow Sampling and Transplants
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy the...
01:28Kidney Transplant I: Introduction
01:26Kidney Transplant II: Surgical Procedure
01:16Kidney Transplant III: Nursing Management
01:22Acute Kidney Injury I: Introduction
01:30Acute Kidney Injury IV: Diagnostic Studies and Prevention